Aims Ameloblastoma is a rare odontogenic tumour with an aggressive local behaviour. Mutations in the mitogen-activated protein kinase pathway, namely BRAF V600E mutations, are a common finding. To date, there is no clear correlation between BRAF V600 mutation and clinical outcome.
Methods We retrospectively reviewed the medical records of patients who underwent surgery for ameloblastoma between May 1998 and June 2018, at 11 participating Italian centres. BRAF mutational status was evaluated by quantitative PCR/pyrosequencing. The primary end points were to determine BRAF mutational status in primitive and recurrent ameloblastoma, and to assess the relapse-free interval (RFI); the secondary end point was to investigate the correlation of BRAF mutational status with the clinical features of the tumour and survival outcomes.
Results Overall, 74 patients were included: 33 (44.5%) were BRAF wild type and 41 (55.4%) BRAF V600 mutated. BRAF V600 mutated ameloblastomas occurred more frequently in younger patients (p=0.0031), were located at the mandible (p=0.0009) and presented with unicystic variant. After a median follow-up of 60 months, 21 (28.3%) patients relapsed (30.3% and 26.8% in the BRAF wild type and BRAF mutated group, respectively). At univariable Cox models, none of the investigated variables, including microscopic margin involvement, was associated with RFI.
Conclusions Local recurrence occurs in 30% of patients with ameloblastoma. BRAFV600 mutation is associated with younger age, mandibular localisation and with unicystic ameloblastoma. Neither BRAF mutation nor microscopically positive surgical margins were associated with RFI. Further studies are needed to elucidate outcomes of this rare disease according to clinical, histopathological and comprehensive molecular features.
- bone neoplasms
Data availability statement
Data are available on reasonable request.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
RB and AI are joint first authors.
AG and MM are joint senior authors.
Handling editor Runjan Chetty.
RB and AI contributed equally.
Correction notice This article has been corrected since it was published Online First. Affiliation of author Eliana Rulli has been corrected.
Collaborators We thank all the members of the Ameloblastoma Cooperative Group for their significant contribution to this work: Camilla Lucca, Laura Moneghini, Alessandro Remigio Bolzoni, Carlo Della Rocca, Giordana Bettini, Giorgia Saia, Stella Vanna Muria, Umberto Mariani, Alessandro Bardazzi, Francesco Erdini, Giovanni Lodi, Aldo Bruno Giannì, Luca Francetti, Alberto Bedogni, Giuseppe Spinelli, Umberto Romeo, Valentino Valentini, Antonella Polimeni, Carlo Della Rocca, Monica Pentenero, Adriano Piattelli, Andrea Cassoni, Matteo Nicolotti, Roberto Pistilli, Massimo Robiony, Antonino Cassisi, Luca Calabrese, and Daniela Massi.
Contributors RB: contributed to conception, design, data acquisition and interpretation, initial draft and final revision of the manuscript. AI: contributed to conception, design, data acquisition and interpretation, initial draft and final revision of the manuscript. GM: contributed to data acquisition, and final revision of the manuscript. ER: contributed to data acquisition and interpretation, initial draft and final revision of the manuscript. AG: contributed to conception, design, supervision and critically revised the manuscript. MM: contributed to conception, design, supervision and critically revised the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.